Amount of liability recognized arising from contingent consideration in a business combination.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 1
-Subparagraph (c)(1)
-URI http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 35
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 25
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476

Name:	us-gaap_BusinessCombinationContingentConsiderationLiability
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

Commitments and Contingencies - Additional Information (Details) - USD ($) $ in Millions	Apr. 02, 2020	Jul. 12, 2019
Janssen Vaccines and Prevention BV [Member] \| License [Member] \| Maximum [Member]
Commitments And Contingencies [Line Items]
Development Based Milestone Payments	$ 1.2
Spitfire Pharma, Inc. [Member] \| Sales Milestones [Member]
Commitments And Contingencies [Line Items]
Future contingent payments		$ 80.0
License agreement term		10 years